Datar Cancer Genetics Receives FDA Clearance for CellDx Tissue Genomic Test

May 15, 2026
Datar Cancer Genetics has received U.S. FDA clearance for its CellDx Tissue assay, a comprehensive genomic profiling test for solid tumors that analyzes DNA and RNA to identify key cancer-related genetic variations.

Datar Cancer Genetics has received clearance from the U.S. Food and Drug Administration for its CellDx Tissue assay, announced in a press release. The comprehensive genomic profiling test is designed for use with solid tumor samples and uses targeted next generation sequencing of DNA and RNA to support clinical decision making.

CellDx Tissue analyzes 517 cancer associated genes, identifying somatic single nucleotide variants, small insertions and deletions, ERBB2 gene amplification, and gene fusions involving ALK, RET, and ROS1. The test is performed at the company’s CAP and CLIA accredited laboratory and is intended to provide standardized genomic information for oncologists.

The FDA clearance follows earlier Breakthrough Device Designations granted to Datar Cancer Genetics for its liquid biopsy platforms. The company stated that the clearance strengthens its ability to collaborate with clinical, academic, and biopharmaceutical partners in research and biomarker development programs.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)
Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Whitepaper

Tensordyne Napier: What If One Rack Could Do the Work of Nine?

Tensordyne

This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.